A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia

Oncologist

Volumn 12, Issue 10, 2007, Pages 1253-1263

  Charu, Veena ^a   Saidman, Bruce ^b   Ben Jacob, Ali ^c   Justice, Glen R ^d   Maniam, Ajit S ^a   Tomita, Dianne ^e   Rossi, Greg ^e   Rearden, Timothy ^f   Glaspy, John ^g  

^a Pacific Cancer Medical Center   (United States)

^b Medical Oncology Associates   (United States)

^c Cache Valley Cancer Treatment and Research Center   (United States)

^d Pacific Coast Hematology/Oncology Medical Group   (United States)

^e AMGEN INC   (United States)

^f Hematology Oncology Consultants   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anemia; Cancer; Chemotherapy; Darbepoetin alfa; Hemoglobin

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYST; DEEP VEIN THROMBOSIS; DEHYDRATION; DRUG DOSE ESCALATION; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; KAPLAN MEIER METHOD; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEOPLASM; PERIPHERAL SWELLING; PNEUMONIA; POLYP; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; THERAPY DELAY; THROMBOEMBOLISM;

AGED; ANEMIA; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 36148949742     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-10-1253     Document Type: Article

References (30)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
2. Stasi R, Abriani L, Beccaglia P et al. Cancer-related fatigue: Evolving concepts in evaluation and treatment. Cancer 2003;98:1786-1801.
3. Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
4. Glaspy JA, Jadeja JS, Justice G et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-276.
5. Demetri GD, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-3425.
6. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
7. Vadhan-Raj S, Mirtsching B, Charu V et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 2003;1:131-138.
8. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
9. Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
10. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-4107.
11. Rodgers GM. NCCN Practice Guidelines in Oncology: Cancer and treatment-related anemia, National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf. Accessed June 1, 2007.
12. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-2216.
13. Bamias A, Aravantinos G, Kalofonos C et al. Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEpo): A prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 2003;64:102-110.
14. Del Mastro L, Venturini M, Lionetto R et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997;15:2715-2721.
15. Thatcher N, De Campos ES, Bell DR et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999;80:396-402.
16. Vansteenkiste J, Tomita D, Rossi G et al. Darbepoetin alfa in lung cancer patients on chemotherapy: A retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline. Support Care Cancer 2004;12:253-262.
17. Tremmel L, Scarpone L. Using MedDRA for adverse events in cancer trials: Experience, caveats, and advice. Drug Inf J 2001;35:845-852.
18. Cella D, Eton DT, Lai JS et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547-561.
19. Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-895.
20. Lyman GH, Glaspy J. Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia?Asystematic review. Cancer 2006;106:223-233.
21. Crawford J, Robert F, Perry MC et al. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. J Thorac Oncol 2007;2:210-220.
22. Boccia R, Malik IA, Raja V et al. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. The Oncologist 2006;11:409-417.
23. Straus DJ, Testa MA, Sarokhan BJ et al. Quality-of-life and health benefits of early treatment of mild anemia: A randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer 2006;107:1909-1917.
24. Ross SD, Allen IE, Henry DH et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature. Clin Ther 2006;28:801-831.
25. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-714.
26. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
27. Overgaard J, Hoff CM, Sand Hansen H et al. Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) - The Danish Head and Neck Cancer Group (DAHANCA 10) randomized trial. 14th European Cancer Conference, Barcelona, Spain, September 23-27, 2007. Abstract 6LB.
28. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005;23:5960-5972.
29. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-1032.
30. Glaspy J, Smith R, Aapro M et al. Results from a phase III, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in patients not receiving chemotherapy or radiotherapy. American Association for Cancer Research, Los Angeles, CA, April 14-18, 2007. Abstract LB-3.